RPID — Rapid Micro Biosystems, Inc.

Summary of Rapid Micro Biosystems Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $11.3 million, a 37% increase year-over-year, marking a quarterly record.
• System Placements: 16 Growth Direct systems placed in Q4, totaling 190 systems globally, with 155 fully validated.
• Product Revenue: Increased 78% to $9.3 million, driven by strong system placements.
• Consumable Revenue: Grew 11% in Q4, with full-year consumable revenue up 17%.
• Recurring Revenue: Increased 15% for the full year, accounting for 53% of total revenue.
• Gross Margin: Q4 gross margin was impacted by inventory-related charges, resulting in a negative margin of 3%. Excluding these charges, gross margin was positive at 7%.
• Net Loss: Q4 net loss of $12.5 million, compared to a net loss of $9.7 million in Q4 2024.
• Cash Position: Ended the year with $39 million in cash and investments.

2. Strategic Updates and Business Highlights

• Partnerships: Announced a significant expansion of the Growth Direct platform with Samsung Biologics, indicating strong customer interest.
• Collaboration with MilliporeSigma: Progressing well, with established customer demo labs across Europe and Asia to enhance sales.
• Product Development: A next-generation cloud-native software platform is expected to launch in the second half of 2026, aimed at enhancing customer experience and generating additional revenue through AI-driven analytics.
• Market Positioning: Strong focus on automation in pharmaceutical manufacturing, with a robust value proposition for both contract development and manufacturing organizations (CDMOs) and principal manufacturers.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected between $37 million and $41 million, with expectations of 30 to 38 system placements.
• Gross Margin Expectations: Anticipated to reach approximately 20% for the full year, with significant improvements expected in the second half.
• Q1 Revenue Forecast: Expected to be at least $7.5 million, including at least 5 system placements.
• Operating Expenses: Projected between $47 million and $51 million for 2026.

4. Bad News, Challenges, or Points of Concern

• Inventory Charges: Q4 gross margin was negatively impacted by a $1.1 million write-off of unusable consumable inventory.
• Net Loss Increase: The net loss widened compared to the previous year, raising concerns about cost management and operational efficiency.
• Validation Delays: The gap between placed and validated systems has widened, which could impact future revenue recognition and operational efficiency.
• Service Revenue Variability: Lower service revenue in Q4 due to timing of validations, which could affect overall margins.

5. Notable Q&A Insights

• Validation Process: Management acknowledged that the timing of validations can vary, leading to a natural lag between system placement and validation completion. They expect this gap to decrease as they work with customers like Amgen.
• Repeat Customers: Repeat customers generally move through the sales and validation process more quickly, which could help improve future revenue streams.
• Cloud-Native Software Integration: The new software platform will be integrated into new orders and could also be monetized for existing customers, enhancing recurring revenue potential.
• Consumable Cost Reductions: Significant cost reductions have been secured with vendors, expected to positively impact gross margins starting in Q2 2026.

Overall, Rapid Micro Biosystems demonstrated strong growth in Q4 2025, but faces challenges related to inventory management and validation processes. The company is optimistic about its strategic partnerships and product innovations, which are expected to drive future growth.